Cui, Xiaoming
Novartis Pharmaceuticals Corporation, East Hanover, NJ
2 papers on CoChatORCID 0000-0003-3091-7496
Most cited papers
- Verified
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 150
- Verified
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 35
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free